Open Journal Systems

Clinical Application of Whole Body Bone Imaging and Tumor Markers in Bone Metastasis of Breast Cancer Patients

Y. Wang (Central Hospital of Chaoyang City, Chaoyang, Liaoning Province, China)

Abstract


Objective. To analyze the clinical application of whole-body bone imaging and tumor markers in breast cancer patients with bone metastasis. Methods. This study chose to investigate our hospital 100 cases of breast cancer patients, the disease case selection time in September 2018 - September 2019, and in all patients after surgery SPECT whole body bone imaging examination and carcinoembryonic antigen, carcinoembryonic antigen (CEA) against the original L-53 (CAL5-3), alkaline phosphatase (ALP), and other tumor markers detection. Patients with bone metastases were treated with radiotherapy and further SPECT whole-body bone imaging and tumor markers were examined after treatment. Results. The sensitivity and specificity of the combined detection of tumor markers in the diagnosis of breast cancer bone metastasis were higher than that of the single detection, and the sensitivity and specificity of the whole body bone imaging detection were higher than that of the combined detection of tumor markers and the single detection. The levels of tumor markers such as CEA (13.05±5.31, 2.48±4.28, 69.54±8.04), serum CAL5-3 (44.27±5.67, 15.08±9.95, 88.18±12.04) and ALP (126.83±47.58, 29.67±18.35, 117.56±36.23) before treatment in grade I, II and III patients showed that the higher the grade of breast cancer bone metastasis was, the higher the grade of breast cancer bone metastasis was. Serum levels of tumor markers are also higher. The number of patients who received radiotherapy for bone metastases of breast cancer was 60, the effective rate was 60%, the ineffective number was 40, and the ineffective rate was 40%. The levels of serum tumor markers before and after treatment were compared between the effective group and the ineffective group. It was found that the levels of CEA, CAL5-3, ALP and other tumor markers in the effective group were 61.15±33.05, 21.28±19.18, 11.86±4.82, 3.27±2.19, 86.33±29.95, 58.73±18.42, respectively, which were lower than those in the ineffective group (P < 0.05). Conclusion. The clinical application of whole-body bone imaging and tumor markers in breast cancer patients with bone metastasis is significant, and the combined effect of the two is higher.


Keywords


Whole body bone imaging; Tumor markers; Breast cancer; Bone metastases.

Full Text:

PDF

References


WANG Si, SONG Liping, ZHANG Xin, et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2, serum tumor markers and the relationship between bone metastasis in breast cancer [J]. Chin J Modem Med, 2020,30 (7):37-41.

Zheng X, Song L P. The value of whole body bone imaging combined with serum CA15-3, CEA, ALP in the diagnosis of breast cancer bone metastasis [J]. Journal of Guangdong Medical Sciences, 2019,40 (16):2326-2330.

Wang RL, Zhang SH, Li GH, et al. Diagnostic value of carcinoembryonic antigen, Ca15-3, tartrate acid phosphatase combined with whole body bone imaging in senile breast cancer bone metastasis [J]. Geriatrics in Practice, 2017,31 (11):1061-1064.

Duan YQ, Xia SP, Wu M, et al. Application of TPINP and ICTP detection, SPECT and CT imaging in breast cancer bone metastasis [J]. Marker Immunoassay and Clinics, 2017, 24(8): 867-869,879. The reggae, the original lily. Journal of Clinical Oncology, 2010, 36 (1):87-91.

Wang Y, Wang Y, Wang Y, et al. The role of serum tumor markers in the early diagnosis of gastric cancer [J].

Xia LJ, Yu Yinhua, Mo QG. Research progress on the mechanism of c-Src in HR+ breast cancer dormant bone metastasis [J]. Journal of Guangxi Medical University, 2020,37 (5) : 967-971.



DOI: http://dx.doi.org/10.30564/amor.v6i4.279

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Y. Wang

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.